Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of Telavancin in Normal and Obese Subjects

Trial Profile

Pharmacokinetics of Telavancin in Normal and Obese Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telavancin (Primary)
  • Indications Bacteraemia; Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Osteomyelitis; Skin and soft tissue infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Jan 2018 Results published in the Antimicrobial Agents and Chemotherapy
    • 25 Apr 2017 Results assessing pharmacokinetics of fixed dose telavancin presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 According to a Theravance Biopharma media release,data from this trial was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top